{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:57:20Z","timestamp":1789192640010,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alexion, AstraZeneca Rare Disease"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fatigue is the most common symptom associated with paroxysmal nocturnal hemoglobinuria (PNH). The objective of this analysis was to estimate values that would suggest a clinically important change (CIC) for the functional assessment of chronic illness therapy-fatigue scale (FACIT-Fatigue) in patients with PNH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults with PNH who initiated eculizumab within 28\u00a0days of enrollment in the International PNH Registry as of January 2021 with baseline FACIT-Fatigue scores were included in the analysis. Distribution-based estimates of likely difference were calculated using 0.5\u2009\u00d7\u2009SD and SEM. Anchor-based estimates of CIC considered the European Organization for Research and Treatment of Cancer (EORTC) global health status\/quality of life summary score and the EORTC Fatigue Scale score. Changes in anchors and high disease activity (HDA) shift from start of eculizumab treatment to each follow-up visit were then assessed by FACIT-Fatigue score change (\u2264\u20091 CIC, no change, or\u2009\u2265\u20091 CIC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline, 93% of 423 patients had fatigue documented in their medical history. The distribution-based estimates for FACIT-Fatigue were 6.5 using 0.5\u2009\u00d7\u2009SD and 4.6 using SEM; internal consistency was high (\u03b1\u2009=\u20090.87). For anchor-based estimates, the FACIT-Fatigue CIC ranged from 2.5 to 15.5, and generally supported 5 points as a reasonable lower end of the value for meaningful individual change. The percentage of patients who changed from having HDA at baseline to no HDA at eculizumab-treated follow-up visits increased over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These results support the use of 5 points as the CIC for FACIT-Fatigue in patients with PNH, which is within range of the CICs reported in other diseases (3\u20135 points).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41687-023-00609-4","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T08:01:50Z","timestamp":1688544110000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Clinically important change for the FACIT-Fatigue scale in paroxysmal nocturnal hemoglobinuria: a derivation from international PNH registry patient data"],"prefix":"10.1186","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9881-4541","authenticated-orcid":false,"given":"David","family":"Cella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutaka","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Tomazos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gustovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami S.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Schrezenmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,5]]},"reference":[{"key":"609_CR1","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1056\/NEJM199511093331904","volume":"333","author":"P Hillmen","year":"1995","unstructured":"Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV (1995) Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 333:1253\u20131258","journal-title":"N Engl J Med"},{"key":"609_CR2","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","volume":"124","author":"RA Brodsky","year":"2014","unstructured":"Brodsky RA (2014) Paroxysmal nocturnal hemoglobinuria. Blood 124:2804\u20132811","journal-title":"Blood"},{"key":"609_CR3","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/cam4.1953","volume":"8","author":"CP Escalante","year":"2019","unstructured":"Escalante CP, Chisolm S, Song J, Richardson M, Salkeld E, Aoki E et al (2019) Fatigue, symptom burden, and health-related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria. Cancer Med 8:543\u2013553","journal-title":"Cancer Med"},{"key":"609_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1365-2141.2004.04992.x","volume":"126","author":"VM Moyo","year":"2004","unstructured":"Moyo VM, Mukhina GL, Garrett ES, Brodsky RA (2004) Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays. Br J Haematol 126:133\u2013138","journal-title":"Br J Haematol"},{"key":"609_CR5","doi-asserted-by":"publisher","first-page":"922","DOI":"10.3324\/haematol.2013.093161","volume":"99","author":"H Schrezenmeier","year":"2014","unstructured":"Schrezenmeier H, Muus P, Socie G, Szer J, Urbano-Ispizua A, Maciejewski JP et al (2014) Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. Haematologica 99:922\u2013929","journal-title":"Haematologica"},{"key":"609_CR6","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s00277-020-04052-z","volume":"99","author":"H Schrezenmeier","year":"2020","unstructured":"Schrezenmeier H, R\u00f6th A, Araten DJ, Kanakura Y, Larratt L, Shammo JM et al (2020) Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry. Ann Hematol 99:1505\u20131514","journal-title":"Ann Hematol"},{"key":"609_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0885-3924(96)00274-6","volume":"13","author":"SB Yellen","year":"1997","unstructured":"Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E (1997) Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. J Pain Symptom Manage 13:63\u201374","journal-title":"J Pain Symptom Manage"},{"key":"609_CR8","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1053\/apmr.2002.36959","volume":"83","author":"D Cella","year":"2002","unstructured":"Cella D, Nowinski CJ (2002) Measuring quality of life in chronic illness: the functional assessment of chronic illness therapy measurement system. Arch Phys Med Rehabil 83:S10\u2013S17","journal-title":"Arch Phys Med Rehabil"},{"key":"609_CR9","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/j.1445-5994.2012.02924.x","volume":"43","author":"I Weitz","year":"2013","unstructured":"Weitz I, Meyers G, Lamy T, Cahn JY, Uranga MT, Garcia Vela JA et al (2013) Cross-sectional validation study of patient-reported outcomes in patients with paroxysmal nocturnal haemoglobinuria. Intern Med J 43:298\u2013307","journal-title":"Intern Med J"},{"key":"609_CR10","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0885-3924(02)00529-8","volume":"24","author":"D Cella","year":"2002","unstructured":"Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE (2002) Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 24:547\u2013561","journal-title":"J Pain Symptom Manage"},{"key":"609_CR11","first-page":"811","volume":"32","author":"D Cella","year":"2005","unstructured":"Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J (2005) Validation of the Functional Assessment of Chronic Illness Therapy Fatigue scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 32:811\u2013819","journal-title":"J Rheumatol"},{"key":"609_CR12","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3899\/jrheum.100799","volume":"38","author":"JS Lai","year":"2011","unstructured":"Lai JS, Beaumont JL, Ogale S, Brunetta P, Cella D (2011) Validation of the functional assessment of chronic illness therapy-fatigue scale in patients with moderately to severely active systemic lupus erythematosus, participating in a clinical trial. J Rheumatol 38:672\u2013679","journal-title":"J Rheumatol"},{"key":"609_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s41687-019-0115-4","volume":"3","author":"D Cella","year":"2019","unstructured":"Cella D, Wilson H, Shalhoub H, Revicki DA, Cappelleri JC, Bushmakin AG et al (2019) Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis. J Patient Rep Outcomes 3:30","journal-title":"J Patient Rep Outcomes"},{"key":"609_CR14","volume-title":"Inc","author":"A Pharmaceuticals","year":"2021","unstructured":"Pharmaceuticals A (2021) Inc. ULTOMIRIS. ravulizumab-cwvz, Boston, MA"},{"key":"609_CR15","unstructured":"Alexion Pharmaceuticals, Inc. Soliris. eculizumab. New Haven, CT; 2020."},{"key":"609_CR16","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/imj.13523","volume":"47","author":"AM Almeida","year":"2017","unstructured":"Almeida AM, Bedrosian C, Cole A, Muus P, Schrezenmeier H, Szer J et al (2017) Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry. Intern Med J 47:1026\u20131034","journal-title":"Intern Med J"},{"key":"609_CR17","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa061648","volume":"355","author":"P Hillmen","year":"2006","unstructured":"Hillmen P, Young NS, Schubert J, Brodsky RA, Soci\u00e9 G, Muus P et al (2006) The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355:1233\u20131243","journal-title":"N Engl J Med"},{"key":"609_CR18","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","volume":"111","author":"RA Brodsky","year":"2008","unstructured":"Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J et al (2008) Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 111:1840\u20131847","journal-title":"Blood"},{"key":"609_CR19","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/j.oret.2021.04.001","volume":"5","author":"R Schwartz","year":"2021","unstructured":"Schwartz R, Warwick A, Olvera-Barrios A, Pikoula M, Lee AY, Denaxas S et al (2021) Evolving treatment patterns and outcomes of neovascular age-related macular degeneration over a decade. Ophthalmol Retina 5:e11\u2013e22","journal-title":"Ophthalmol Retina"},{"key":"609_CR20","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","volume":"133","author":"AG Kulasekararaj","year":"2019","unstructured":"Kulasekararaj AG, Hill A, Rottinghaus ST, Langemeijer S, Wells R, Gonzalez-Fernandez FA et al (2019) Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood 133:540\u2013549","journal-title":"Blood"},{"key":"609_CR21","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","volume":"133","author":"JW Lee","year":"2019","unstructured":"Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, Pessoa V, Gualandro S, Fureder W et al (2019) Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood 133:530\u2013539","journal-title":"Blood"},{"key":"609_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.rdc.2018.01.011","volume":"44","author":"L Engel","year":"2018","unstructured":"Engel L, Beaton DE, Touma Z (2018) Minimal clinically important difference: a review of outcome measure score interpretation. Rheum Dis Clin North Am 44:177\u2013188","journal-title":"Rheum Dis Clin North Am"},{"key":"609_CR23","unstructured":"Administration FaD. Public Workshop on Patient-Focused Drug Development: Guidance 4\u2014Incorporating Clinical Outcome Assessments into Endpoints for Regulatory Decision Making. https:\/\/www.fda.gov\/media\/132505\/download. Accessed 17 Jan 2023"},{"key":"609_CR24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jclinepi.2021.12.009","volume":"144","author":"G Partington","year":"2021","unstructured":"Partington G, Cro S, Mason A, Phillips R, Cornelius V (2021) Design and analysis features used in small population and rare disease trials: a targeted review. J Clin Epidemiol 144:93\u2013101","journal-title":"J Clin Epidemiol"},{"key":"609_CR25","first-page":"13","volume":"34","author":"D Cella","year":"1997","unstructured":"Cella D (1997) The functional assessment of cancer therapy-anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34:13\u201319","journal-title":"Semin Hematol"},{"key":"609_CR26","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/BF00435226","volume":"2","author":"E Lydick","year":"1993","unstructured":"Lydick E, Epstein RS (1993) Interpretation of quality of life changes. Qual Life Res 2:221\u2013226","journal-title":"Qual Life Res"},{"key":"609_CR27","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/S0895-4356(99)00071-2","volume":"52","author":"KW Wyrwich","year":"1999","unstructured":"Wyrwich KW, Tierney WM, Wolinsky FD (1999) Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 52:861\u2013873","journal-title":"J Clin Epidemiol"},{"key":"609_CR28","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365\u2013376","journal-title":"J Natl Cancer Inst"},{"key":"609_CR29","volume-title":"EORTC QLQ-C30 scoring manual","author":"P Fayers","year":"2001","unstructured":"Fayers P, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) EORTC QLQ-C30 scoring manual, 3rd edn. European Organisation for Research and Treatment of Cancer, Brussel","edition":"3"},{"key":"609_CR30","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","volume":"61","author":"D Revicki","year":"2008","unstructured":"Revicki D, Hays RD, Cella D, Sloan J (2008) Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 61:102\u2013109","journal-title":"J Clin Epidemiol"},{"key":"609_CR31","unstructured":"Hill QA, Roth A, Jilma B, Broome CM, Berentsen S, Rizio AA et al (2021) Clinically important change in FACIT-Fatigue score for patients with cold agglutinin disease: an analysis using the phase 3 CARDINAL and CADENZA studies. Presented at: European Hematology Association, June 9\u201317, 2021; Virtual Congress"},{"key":"609_CR32","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1177\/0194599819852604","volume":"161","author":"AR Sedaghat","year":"2019","unstructured":"Sedaghat AR (2019) Understanding the minimal clinically important difference (MCID) of patient-reported outcome measures. Otolaryngol Head Neck Surg 161:551\u2013560","journal-title":"Otolaryngol Head Neck Surg"},{"key":"609_CR33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s43019-020-00038-3","volume":"32","author":"S Maredupaka","year":"2020","unstructured":"Maredupaka S, Meshram P, Chatte M, Kim WH, Kim TK (2020) Minimal clinically important difference of commonly used patient-reported outcome measures in total knee arthroplasty: review of terminologies, methods and proposed values. Knee Surg Relat Res 32:19","journal-title":"Knee Surg Relat Res"},{"key":"609_CR34","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12955-020-01398-w","volume":"18","author":"P Woaye-Hune","year":"2020","unstructured":"Woaye-Hune P, Hardouin JB, Lehur PA, Meurette G, Vanier A (2020) Practical issues encountered while determining minimal clinically important difference in patient-reported outcomes. Health Qual Life Outcomes 18:156","journal-title":"Health Qual Life Outcomes"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-023-00609-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-023-00609-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-023-00609-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T08:08:19Z","timestamp":1688544499000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-023-00609-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,5]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["609"],"URL":"https:\/\/doi.org\/10.1186\/s41687-023-00609-4","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,5]]},"assertion":[{"value":"19 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The International PNH Registry was approved by the institutional review boards (or equivalent) of participating centers, and all patients provided written informed consent before inclusion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"D. Cella is the President of FACIT.org and has received research support and consulting fees from Alexion, AstraZeneca Rare Disease. P. Johansson has no conflicts of interest to disclose. Y. Ueda has served as a consultant and received honoraria from Alexion, AstraZeneca Rare Disease, Sanofi, Chugai, and Novartis, and research funding from Chugai. P. Gustovic, A. Wang, and AS Patel are employees of Alexion, AstraZeneca Rare Disease. I Tomazos was an employee of Alexion, AstraZeneca Rare Disease at the time of the study. H Schrezenmeier has received travel support, honoraria, and research support (to institution) from Alexion, AstraZeneca Rare Disease, and Novartis, and honoraria (to University of Ulm) from Roche, Apellis, and Sanofi.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"63"}}